Search for Clinical Trial Results

Sponsored By

Paramyxoviridae Infections - 16 Studies Found

Status Study
Completed Study Name: An Open Label Study to Examine the Effects of DAS181 Administered by Dry Powder Inhaler (DPI) or Nebulized Formulation in Immunocompromised Subjects With Parainfluenza (PIV) Infection
Condition: Parainfluenza
Date: 2013-07-11
Interventions:
  • Drug: DAS181-F02 Dry Powder in Bulk

Active, not recruiting Study Name: A Phase II, Randomized, Double-blind, Placebo-controlled Study to Examine the Effects of DAS181 in Immunocompromised Subjects With Lower Respiratory Tract Parainfluenza Infection on Supplemental Oxygen
Condition: Parainfluenza
Date: 2012-07-17
Interventions:
  • Drug: DAS181 dry powder, formulation F02
  • D
Completed Study Name: Safety of a Live Attenuated Human Parainfluenza Virus Type 2 (HPIV2) Vaccine for Adults, Children, and Infants
Condition: Human Parainfluenza Virus 2
Date: 2010-06-07
Interventions:
  • Biological: Standard Dose HPIV2 Vaccine

Withdrawn Study Name: DAS181 in Patients With Parainfluenza
Condition: Parainfluenza Infection
Date: 2011-09-24
Interventions:
  • Drug: DAS181 20 mg per day of

Completed Study Name: Safety of and Immune Response to Recombinant Live-Attenuated Parainfluenza Type 1 Virus Vaccine
Condition:
  • Parainfluenza
  • Virus Diseases

Date: 2008-03-05
Interventions:
  • Biological: rHPIV1 84/del170/942A, Lot PIV1 #104A vaccine

Recruiting Study Name: A Study to Assess the Safety of Live Intranasal Sendai Virus Vaccine in Children and Toddlers
Condition:
  • Parainfluenza
  • Respiratory Viral Infections

Date: 2005-09-12
Interventions: Biological: Sendai virus vaccine Enders strain; a live, unmodified intranasally administered Sendai viru
Completed Study Name: Safety, Efficacy and Pharmacokinetics of BTA-C585 in a RSV Viral Challenge Study
Condition: Respiratory Syncytial Virus (RSV) Infection
Date: 2016-03-21
Interventions:
  • Drug: BTA-C585 oral capsule Ot
Recruiting Study Name: Evaluating the Infectivity, Safety, and Immunogenicity of a Single Dose of a Recombinant Live-Attenuated Respiratory Syncytial Virus Vaccine (D46/NS2/N/ΔM2-2-HindIII) in RSV-Seronegative Infants 6 to 24 Months of Age
Condition: Respiratory Syncytial Virus Infections
Date: 2017-03-23
Interventions:
  • Biological: D46/NS2/N/ΔM2-2-HindIII

Recruiting Study Name: Infectivity, Safety and Immunogenicity of a Recombinant Live-Attenuated Respiratory Syncytial Virus Vaccine (D46/NS2/N/ΔM2-2-HindIII) in RSV-Seronegative Infants and Children 6 to 24 Months of Age
Condition: Respiratory Syncytial Virus Infections
Date: 2017-03-28
Interventions:
  • Biological: RSV D46/NS2/N/ΔM2-2-HindIII Vaccine

Active, not recruiting Study Name: A Study to Rank Different Dosages of Antigen of GlaxoSmithKline (GSK) Biologicals' Investigational Respiratory Syncytial Virus (RSV) Vaccine (GSK3003891A), Based on Their Immune Response and Safety, When Administered to Healthy Adult Women
Condition: Respiratory Syncytial Virus Infections
Date: 2016-11-03
Interventions:
  • Biological: RSV Vaccine (GSK3003891A) formulation 1

Next >>>